Citations

Clear

15 citation(s) found for "Schlumberger, W".

Real-world practice patterns of IDH inhibitors and outcomes of on-label IDH inhibitor use for Acute Myeloid Leukemia in the United States
Leone, Sami, Dworkin, Emily , Kahla, Justin A. , Ali, Moiez , Raptis, Nepheli, Lokhandwala, Alifya, Taborda, Cristian , Ritchie, Jordan, Coltoff, Alexander , Ormond, Sean, Dulak, Dominika, Im, Annie , Song, Amy , Scobie, Micaela R. , Lewis-Gonzalez, Jessica, Foucar, Charles , LeBlanc, Thomas W. , Pulte, Dianne , Wynne, Joseph , Leblanc, Thomas , Lin, Chenyu , Woods, Ashley C. , Li, Zhiguo , Leone, Sami, Abaza, Yasmin , Filho, Cilomar Martins de Oliveira , Lee, Michelle Hyunju , Bewersdorf, Jan Philipp , Burkart, Madelyn , Kumar, Mahesh , Song, Amy, Iyer, Sunil Girish , Murthy, Guru Subramanian Guru , Zhou, Katherine Ismei , Atallah, Ehab , Winer, Eric P. , Erba, Harry Paul , Patel, Anand , Badar, Talha , Norsworthy, Kelly J.

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 1614-1614

10.1182/blood-2025-1614 Get It

Abstract Introduction: Isocitrate dehydrogenase (IDH) mutations are observed in ~20% of patients with acute myeloid leukemia (AML). In the U.S., ivosidenib (ivo) is approved with or without azacitidine (aza) in the frontline (FL) and as monotherapy in relapsed/refractory (R/R) IDH1-mutated (mut) AML. Olutasidenib (oluta) is approved as monotherapy for R/R IDH1-mut AML. Enasidenib (ena) is approved as monotherapy for R/R IDH2-mut AML. This study describes real-world IDH inhibitor (IDHi) administration patterns and evaluates their outcomes in on-label settings. Methods: A retrospective review of patients with IDH1/2-mut AML who received ivosidenib, olutasidenib, or enasidenib was conducted at 12 academic institutions in the U.S. Best response at any time during treatment, including complete response (CR) and complete response with partial hematologic recovery (CRh), were graded using European Leukemia Net (ELN) 2022 criteria. Results: A total of 387 patients with IDH1- and IDH2-mut AML were treated with an IDHi in the FL or R/R setting. Median follow-up was 9.6 months (range, 0.03-90.7). Demographics include 79% White, 14% Black, 3% Asian, and 4% other/unknown race; 5% were Hispanic ethnicity; 46% were female; the median age was 70 years (range, 28-95). 70% had an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, 26% had secondary AML, and 10% had therapy-related AML. Per the ELN 2024 less-Intensive risk classification, 58% were favorable risk, 29% intermediate, 7% adverse, and 6% unknown. Overall, 209 of 387 patients (54%) received IDHi regimens on-label. In FL IDH1-mut AML (n=45), 11 received ivo monotherapy, 25 aza/ivo, and 9 used off-label combinations: 3 hypomethylating agent (HMA) + venetoclax (ven) + ivo, 5 decitabine/ivo, 1 intensive chemotherapy (IC)/ivo. Among R/R IDH1-mut AML (n=109), 47 received ivo monotherapy, 7 oluta monotherapy, and 55 off-label (31 HMA/ivo, 16 HMA/ven/ivo, 3 IC/ivo, and 5 other). 44 received off-label ena for FL treatment of IDH2-mut AML (25 ena monotherapy, 9 HMA/ena, 8 HMA/ven/ena, and 2 IC/ena). In R/R IDH2-mut AML (n=189), 119 patients received ena monotherapy and 70 received off-label combinations (25 HMA/ena, 30 HMA/ven/ena, 7 IC/ena, 6 ena/gilteritinib, and 2 other). In on-label treatment of FL IDH1-mut AML, one of four patients with response assessment of FL ivo monotherapy had a CR/CRh. Of 19 patients with response assessment on FL aza/ivo, 13 patients (68.4%) had a CR as best response (95% CI, 46.0-84.6%). Median OS was 14.9 mo (95% CI, 4.17-NR) for ivo monotherapy (n=11) and 31.9 mo (95% CI, 9.1-NR) for aza/ivo (n=25), with 0 and 2 patients receiving allogeneic stem cell transplant (allo-SCT), respectively. In R/R IDH1-mut AML, the rate of CR/CRh was 35.5% (95% CI, 21.1-53.1) for on-label ivo monotherapy. All 4 patients with response assessment for on-label oluta monotherapy had a CR. Median OS was 14.0 mo (95% CI, 10.1-22.4) for ivo monotherapy and NR for oluta monotherapy (95% CI, 10.1-NR), with 10 and 0 receiving allo-SCT, respectively. The CR/CRh rate for ivo was 38.1% (8 of 21 assessed; 95% CI, 20.8-59.1) in age < 70, and 30.0% (3 of 10 assessed; 95% CI, 10.8-60.3) in age ≥ 70. Median OS was 15.2 mo (95% CI 9.3-NR) in age < 70 (n=27) and 10.4 mo (95% CI 8.0-18) in age ≥ 70 (n=20). In R/R IDH2-mut AML, the rate of CR/CRh for on-label ena monotherapy was 38.2% (95% CI, 27.6-50.1). Median OS was 12.1 mo (95% CI, 8.2-16.6), with 5 having received allo-SCT. In demographic subgroups for ena monotherapy, 52 non-Hispanic White (NHW) patients with response assessment had a CR/CRh rate of 42.3% (95% CI, 0.30-0.56). Only 1 of 13 non-Hispanic Black (NHB) patients with response assessment had a CRh (7.7%; 95% CI, 1.4-33.0) as best response, with none attaining CR. Median OS was 13.7 mo (95% CI 10.3-26.3) in NHW (n=82), 11.2 mo (95% CI, 6.1-NR) in NHB (n=18), and 69.1 mo (95% CI, 52.6-NR) in Hispanic patients (n=8). The CR/CRh rate was 48.6% (17 of 35 assessed; 95% CI, 33.0-64.4) for age < 70, and 27.3% (9 of 33 assessed; 95% CI, 15.1-44.2) for age ≥ 70. Median OS was 12.0 mo (95% CI, 9.9-22.1) in age < 70 (n=48) and 5.8 mo (95% CI, 4.1-8.7) in age ≥ 70 (n=69). Conclusion: Practice patterns for IDH inhibitors in AML vary considerably, with high amounts of off-label use. Response rates for ivosidenib and enasidenib in the real-world setting are comparable to those of clinical trials. Descriptive analyses of demographic subgroups highlight areas in need of further research.
Clinical and pathological spectrum of disease severity among patients with acute liver failure (ALF) undergoing deceased donor liver transplantation
Tujios, Shannan R. , Sussman, Norman , Rakela, Jorge , Ganger, Daniel , Bass, Nathan M., Reuben, Adrian , Stravitz, R. Todd, Wang, Hanlin , Peng, Lan, Yeh, Matthew M., Hatfield, Bryce , Lee, William M. , Group, for the Acute Liver Failure Study, Rakela, Jorge L, Lee, William M , Rule, Jody A. , Kleiner, David Erwin , Choi, Eun-Young Karen , Yang, Guang‐Yu , Gill, Ryan M. , Fontana, Robert J. , Group, for the Acute Liver Failure Study

Mayo Clinic

Liver Transplantation | May 9, 2025 | Volume: 31 | Issue: 11 | Pages: 1368-1378

10.1097/lvt.0000000000000634 | PMID 40341552 Get It

Listing and transplanting patients with acute liver failure (ALF) is challenging, requiring rapid assessment of the likelihood of recovery. The availability of a large number of ALF liver explants, along with their clinical data, afforded an opportunity to retrospectively evaluate liver transplantation (LT) decision-making. We hypothesized that, with the benefit of hindsight, a small number of patients might have recovered without LT. Three hundred liver explants from ALF patients of varying etiologies who had undergone LT over 22 years in the Acute Liver Failure Study Group registry were reviewed for histopathological features and degree of necrosis by a committee of 8 hepatopathologists. A second committee of 8 experienced transplant hepatologists independently reviewed clinical data on these same 300 patients and retrospectively scored the likelihood that each patient required transplantation. Only 3 (1%) of those reviewed by the Clinical Committee were considered to “Definitely” not require liver grafting, while an additional 10 (3.3%) were deemed to “Possibly” not require transplantation (Not Likely Group, N=13). There was no difference in the degree of necrosis in explants in these groups, when compared to the remaining Likely Group, N=287 (95.6%), except in acetaminophen (APAP)-associated ALF, where the degree of necrosis was more uniformly graded as severe, correlating with the need for transplantation. Virtually every patient undergoing LT for ALF retrospectively appeared to need their transplant, based on expert clinical consensus review. Overall, there was poor correlation between clinical severity and apparent degree of necrosis seen in the 300 liver explants, except perhaps for APAP subjects.
Anti-CD3 Mono-Fab co-potentiates TCR antigen recognition in human T cells
Becher, Laura , Nevala, Wendy K. , Sutor, Shari L., Abergel, Megan , Hoffmann, Michele, Parks, C., Pease, Larry R. , Pages, Diana Gil, Hoffmann, Michele M., Parks, Christopher, Schrum, Adam G. , Markovic, Svetomir N.

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 204 | Issue: 1_Supplement | Pages: 145.44-145.44

10.4049/jimmunol.204.supp.145.44 Get It

Abstract TCR mediated antigen recognition results in a signaling cascade leading to T cell activation. Antigen binding to its cognate TCR drives receptor aggregation and conformational changes that trigger signaling from the receptor. Conformational change in the CD3 complex (CD3Δc) is required for robust signaling and productive T cell responses. In contrast, weakly recognized antigens do not induce CD3Δc and the resulting T cell response is poor. Thus, T cell responses to weak antigens may be improved by induction of CD3Δc. We previously described an anti-mouse CD3ɛ monovalent Fab (Mono-7D6-Fab) that induced CD3Δc and synergized with weak antigens to enhance the T cell response, a process we termed co-potentiation. However, Mono-7D6-Fab did not induce classical T cell signaling in the absence of antigenic ligation. Mono-7D6-Fab effectively co-potentiated T cells against murine B16-F10 melanoma cells and reduced tumor burden in vivo in a T cell dependent manner. We exploited a model of human cytomegalovirus (CMV) to generate proof of concept that co-potentiation may enhance T cell antigen recognition in humans. Anti-human CD3ɛ monovalent Fab (Mono-OKT3-Fab) improved the CD8 T cell response to the CMV pp65495–503 peptide as measured by increased T cell proliferation, cytokine production, and the ability to kill target cells. Co-potentiation was dependent on antigen specificity, as 1) the effects were dampened when antigen recognition was impaired and 2) sequencing of the TCRs revealed a restricted number of expanded TCR clones. Our results suggest that Mono-OKT3-Fab may have therapeutic clinical applications to achieve a more robust antigen-specific T cell response in the context of diverse human disease, from cancer to chronic infection.
A role for CD3 conformation in the preTCR/CD3 complex (P4428)
Parks, C., Pages, Diana Gil, Hoffmann, Michele, Parks, Christopher

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 190 | Issue: Supplement_1 | Pages: 52.34-52.34

10.4049/jimmunol.190.supp.52.34 Get It

Abstract Mature T cells recognize and respond to antigens through the T cell antigen receptor (TCR). We have established that upon TCR antigenic engagement, the TCR/CD3 complex undergoes a conformational change (CD3dc) of its CD3 epsilon tails to expose a proline-rich sequence and allow downstream signaling to occur. CD3dc has been shown to be required for full TCR/CD3 signaling and function of mature T cells. Pre-TCR assembly with the CD3 complex serves as a developmental checkpoint that ensures the expression of a function variant TCRβ chain in thymocytes. Interestingly, stimulation of the preTCR complex has been found to be ligand-independent; assembly is sufficient. Knowing this, we first determined the stoichiometry of the preTCR/CD3 complex and asked the question, how does assembly impact its ability to undergo conformational change? To answer this question, we employed various novel biochemical methods developed in our laboratory including a flow-cytommetry based immunoprecipitation (IP-FCM) as well as a CD3-pull down assay (CD3-PD). We aim to study the conformation of CD3 in the preTCR/CD3 complex and establish whether or not the assembly of this receptor is enough to induce the active CD3 conformation that supports functional CD3 signaling in mature cells. With our data, we are further able to characterize previously unstudied requirements for CD3 conformational change in the preTCR/CD3 complex with the potential of using this knowledge to manipulate CD3dc in the future.
Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer
Wirth, Lori J. , Brose, Marcia S. , Sherman, Eric J. , Licitra, Lisa , Schlumberger, Martin , Bible, Keith C. , Rodien, Patrice , Godbert, Yann , Fouchardière, Christelle de la , Newbold, Kate, Nutting, Christopher M. , Misir, Soamnauth, Xie, Ran , Almonte, A., Ye, Weifei, Sherman, Steven I , Bible, Keith C , De La Fouchardiere, Christelle , Xie, Ran , Cabanillas, Maria E , Licitra, Lisa , Sherman, Steven I. , Robinson, Bruce , Cabanillas, Maria E.

Mayo Clinic

Journal of Clinical Oncology | May 7, 2021 | Volume: 39 | Issue: 21 | Pages: 2359-2366

10.1200/jco.20.03093 | PMID 33961488 Get It

PURPOSE Anaplastic thyroid cancer (ATC), an aggressive malignancy, is associated with a poor prognosis and an unmet need for effective treatment, especially for patients without BRAF mutations or NTRK or RET fusions. Lenvatinib is US Food and Drug Administration–approved for radioiodine-refractory differentiated thyroid cancer and has previously demonstrated activity in a small study of patients with ATC (n = 17). We aimed to further evaluate lenvatinib in ATC. METHODS This open-label, multicenter, international, phase II study enrolled patients with ATC, who had ≥ 1 measurable target lesion, to receive lenvatinib 24 mg once daily. The primary end points were objective response rate (ORR) by investigator assessment per RECIST v1.1 and safety. Responses were confirmed ≥ 4 weeks after the initial response. Additional end points included progression-free survival and overall survival (OS). RESULTS The study was halted for futility as the minimum ORR threshold of 15% was not met upon interim analysis. The interim analysis set included the first 20 patients. The full analysis set includes all 34 enrolled and treated patients. In the full analysis set, one patient achieved a partial response (ORR, 2.9%; 95% CI, 0.1 to 15.3). More than half of the evaluable patients experienced tumor shrinkage; three patients experienced a > 30% tumor reduction. The median progression-free survival was 2.6 months (95% CI, 1.4 to 2.8); the median overall survival was 3.2 months (95% CI, 2.8 to 8.2). The most common treatment-related adverse events (AEs) were hypertension (56%), decreased appetite (29%), fatigue (29%), and stomatitis (29%). No major treatment-related bleeding events or grade 5 treatment-related AEs occurred. CONCLUSION The safety profile of lenvatinib in ATC was manageable, and many AEs were attributable to the progression of ATC. The results suggest that lenvatinib monotherapy may not be an effective treatment for ATC; further investigation may be warranted.
Salivary and lacrimal dysfunction after radioactive iodine for differentiated thyroid cancer: American Head and Neck Society Endocrine Surgery Section and Salivary Gland Section joint multidisciplinary clinical consensus statement of otolaryngology, ophtha
Singer, Michael C. , Marchal, Francis, Bernet, Vic, Boucai, Laura , Buchholzer, Samanta , Burkey, Brian B., Eisele, David W. , Faure, Fréderic , Freitag, Suzanne K. , Gillespie, M. Boyd , Harrell, R. Mack, Hartl, Dana M. , Haymart, Megan R. , Leffert, Jonathan, Mandel, Susan J., Miller, Barbra S. , Pearce, Elizabeth N. , Rahmati, Rahmatullah, Ryan, William R. , Schaitkin, Barry M., Schlumberger, Martin, Stack, Brendan C. , Nostrand, Doug Van, Wong, Ka Kit , Stack, Brendan C , Pearce, Elizabeth N , Angelos, Peter , Bernet, Victor , Buchholzer, Samanta , Erkul, Evren , Morris, John, Nostrand, Douglas Van , Randolph, Gregory William

Mayo Clinic

Head & Neck | August 26, 2020 | Volume: 42 | Issue: 11 | Pages: 3446-3459

10.1002/hed.26417 | PMID 32812307 Get It

AbstractBackgroundPostoperative radioactive iodine (RAI) administration is widely utilized in patients with differentiated thyroid cancer. While beneficial in select patients, it is critical to recognize the potential negative sequelae of this treatment. The prevention, diagnosis, and management of the salivary and lacrimal complications of RAI exposure are addressed in this consensus statement.MethodsA multidisciplinary panel of experts was convened under the auspices of the American Head and Neck Society Endocrine Surgery and Salivary Gland Sections. Following a comprehensive literature review to assess the current best evidence, this group developed six relevant consensus recommendations.ResultsConsensus recommendations on RAI were made in the areas of patient assessment, optimal utilization, complication prevention, and complication management.ConclusionSalivary and lacrimal complications secondary to RAI exposure are common and need to be weighed when considering its use. The recommendations included in this statement provide direction for approaches to minimize and manage these complications.
American Thyroid Association Guidelines on the Management of Thyroid Nodules and Differentiated Thyroid Cancer Task Force Review and Recommendation on the Proposed Renaming of Encapsulated Follicular Variant Papillary Thyroid Carcinoma Without Invasion to
Haugen, Bryan R. , Sawka, Anna M. , Alexander, Erik K. , Bible, Keith C. , Doherty, Gerard M. , Mandel, Susan J., Pacini, Furio , Schlumberger, Martin, Schuff, Kathryn G., Somerset, Hilary, Steward, David L. , Wartofsky, Leonard , Williams, Michelle D. , Caturegli, Patrizio , Morris, John C., Nassar, Aziza , Sherman, Steven I. , Sosa, Julie Ann

Mayo Clinic

Thyroid | January 23, 2017 | Volume: 27 | Issue: 4 | Pages: 481-483

10.1089/thy.2016.0628 | PMID 28114862 Get It

2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
Haugen, Bryan R. , Alexander, Erik K. , Bible, Keith C. , Doherty, Gerard M. , Mandel, Susan J., Pacini, Furio , Sawka, Anna M. , Schlumberger, Martin , Schuff, Kathryn G., Sherman, Steven I. , Steward, David L. , Tuttle, R. Michael , Wartofsky, Leonard , Nikiforov, Yuri E. , Randolph, Gregory William , Sosa, Julie Ann , Sherman, Steven I

Mayo Clinic

Thyroid® | October 14, 2015 | Volume: 26 | Issue: 1 | Pages: 1-133

10.1089/thy.2015.0020 | PMID 26462967 Get It

Background: Thyroid nodules are a common clinical problem, and differentiated thyroid cancer is becoming increasingly prevalent. Since the American Thyroid Association's (ATA's) guidelines for the management of these disorders were revised in 2009, significant scientific advances have occurred in the field. The aim of these guidelines is to inform clinicians, patients, researchers, and health policy makers on published evidence relating to the diagnosis and management of thyroid nodules and differentiated thyroid cancer. Methods: The specific clinical questions addressed in these guidelines were based on prior versions of the guidelines, stakeholder input, and input of task force members. Task force panel members were educated on knowledge synthesis methods, including electronic database searching, review and selection of relevant citations, and critical appraisal of selected studies. Published English language articles on adults were eligible for inclusion. The American College of Physicians Guideline Grading System was used for critical appraisal of evidence and grading strength of recommendations for therapeutic interventions. We developed a similarly formatted system to appraise the quality of such studies and resultant recommendations. The guideline panel had complete editorial independence from the ATA. Competing interests of guideline task force members were regularly updated, managed, and communicated to the ATA and task force members. Results: The revised guidelines for the management of thyroid nodules include recommendations regarding initial evaluation, clinical and ultrasound criteria for fine-needle aspiration biopsy, interpretation of fine-needle aspiration biopsy results, use of molecular markers, and management of benign thyroid nodules. Recommendations regarding the initial management of thyroid cancer include those relating to screening for thyroid cancer, staging and risk assessment, surgical management, radioiodine remnant ablation and therapy, and thyrotropin suppression therapy using levothyroxine. Recommendations related to long-term management of differentiated thyroid cancer include those related to surveillance for recurrent disease using imaging and serum thyroglobulin, thyroid hormone therapy, management of recurrent and metastatic disease, consideration for clinical trials and targeted therapy, as well as directions for future research. Conclusions: We have developed evidence-based recommendations to inform clinical decision-making in the management of thyroid nodules and differentiated thyroid cancer. They represent, in our opinion, contemporary optimal care for patients with these disorders.
SPE HSE Conference Identifies Challenges and Opportunities for the 21st Century
Visser, Koos, Roger, J, Ognedal, Magne, Strecker, Ian, Corrie, Carlos C., Thoem, T., Hassanali, Khalid M., Molenaar, Donald M.

Mayo Clinic

Journal of Petroleum Technology | February 24, 2015 | Volume: 51 | Issue: 04 | Pages: 22-24

10.2118/0499-0022-jpt Get It

Conference review - No abstract available.
Use of Radioactive Iodine in Patients with Papillary and Follicular Thyroid Cancer: Towards A Selective Approach
Schlumberger, Martin

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | January 8, 2014 | Volume: 83 | Issue: 12 | Pages: 4201-4203

10.1210/jcem.83.12.5293-3 Get It